Preparation for an application to the Horizon Europe EIC Accelerator programme.
| Reference number | |
| Coordinator | Bonsai Biotherapeutics AB |
| Funding from Vinnova | SEK 165 600 |
| Project duration | June 2026 - November 2026 |
| Status | Ongoing |
| Call | Planning grant for international proposal 2026 |
Purpose and goal
The purpose is to strengthen Bonsai Biotherapeutics’ ability to secure funding through the Horizon Europe EIC Accelerator. The objective is to develop a competitive and well-positioned application that clearly demonstrates TOL2’s innovation, market potential, business model, and implementation plan for clinical development in myasthenia gravis.
Expected effects and result
The project is expected to result in a completed and competitive EIC Accelerator application with strengthened strategy, market positioning, and investment case. In the longer term, it may contribute to securing funding for the first clinical study of TOL2, enabling further development of a disease-modifying treatment for patients with myasthenia gravis.
Planned approach and implementation
The project will be carried out with support from external experts in EIC Accelerator applications. Activities include refinement of the business plan, market strategy, financing plan, and investment case, as well as quality assurance against EIC criteria for excellence, impact, and implementation. The outcome will be a completed application ready for submission.